ストックスクリーナーアプリを入手
3.98
2.21%
-0.09
前日終値:
$4.07
開ける：
$4.1
24時間の取引高:
803.69K
Relative Volume:
1.11
時価総額：
$223.69M
収益：
-
当期純損益:
$-57.44M
株価収益率:
-2.9788
EPS:
-1.3361
ネットキャッシュフロー:
$-56.46M
1週間 パフォーマンス:
+9.04%
1か月 パフォーマンス:
-13.48%
6か月 パフォーマンス:
-23.17%
1年 パフォーマンス:
+33.56%
1日の値動き範囲:
$3.97
$4.20
1週間の範囲:
$3.645
$4.20
52週間の値動き範囲:
$2.77
$7.82
Protara Therapeutics Inc Stock (TARA) Company Profile
名前
Protara Therapeutics Inc
セクター
電話
646-844-0337
住所
345 PARK AVENUE SOUTH, NEW YORK, NY
Compare TARA vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TARA
Protara Therapeutics Inc
|
3.98 | 223.69M | 0 | -57.44M | -56.46M | -1.3361 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-04 | 開始されました | JP Morgan | Overweight |
| 2026-01-07 | 開始されました | Piper Sandler | Overweight |
| 2025-04-16 | 開始されました | Scotiabank | Sector Outperform |
| 2025-03-14 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-07-10 | 再開されました | Guggenheim | Buy |
| 2021-06-04 | 開始されました | H.C. Wainwright | Buy |
| 2021-02-17 | 開始されました | Oppenheimer | Outperform |
| 2020-10-19 | 開始されました | Cowen | Outperform |
| 2020-07-29 | 開始されました | Guggenheim | Buy |
すべてを表示
Protara Therapeutics Inc (TARA) 最新ニュース
Protara Therapeutics Inc (TARA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Protara Therapeutics Inc (TARA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Protara Therapeutics Inc (TARA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Protara Therapeutics Inc (TARA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Protara Therapeutics Inc (TARA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Protara Therapeutics Inc (TARA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Protara Therapeutics Inc (TARA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Protara Therapeutics Inc (TARA) Institutional Confidence - TradingKey
Protara (TARA) director granted 31,000 stock options at $3.94 strike - Stock Titan
Protara Therapeutics (TARA) awards director 31,000 stock options at $3.94 - Stock Titan
Protara Therapeutics (TARA) director awarded 31,000 stock options at $3.94 strike - Stock Titan
Cynthia Smith granted 31,000 stock options at Protara Therapeutics (TARA) - Stock Titan
Jane Huang awarded 31,000 Protara (TARA) stock options as director grant - Stock Titan
Director at Protara Therapeutics (NASDAQ: TARA) awarded 31,000 stock options at $3.94 - Stock Titan
Protara (TARA) director receives 31,000 stock options at $3.94 strike - Stock Titan
Protara Therapeutics Inc (TARA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Protara Therapeutics Stockholders Approve Governance and Share Increases - TipRanks
Protara Therapeutics (TARA) investors approve share increase and pay items - Stock Titan
Protara Therapeutics Inc. (TARA) Gains 1.41% as Stock Nears Key ResistanceRevenue Weighted - newsline.com
Does TARA Stock’s 15% After-Hours Slump Signal A Bargain After New Bladder Cancer Data? - Stocktwits
Protara Therapeutics (TARA) Q1 2026 Earnings: Narrower-than-Expected Loss Drives Stock GainTangible Book Value - newsline.com
Protara Therapeutics (TARA) Dips 3.8% as Stock Nears Key Support LevelTrend Following Picks - newsline.com
Protara Therapeutics Q1 2026 Earnings: EPS Beat Driven by Expense Management, Stock SlipsStrong Earnings Momentum - newsline.com
Protara Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift SentimentEarnings Recovery Stocks - newsline.com
Protara Therapeutics (NASDAQ: TARA) CCO has 6,008 RSU shares withheld for taxes - Stock Titan
The Prognosis For Palvella Therapeutics (NASDAQ:PVLA) - Seeking Alpha
Protara Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
What's Driving Protara's Recent Surge - Kavout
Protara Therapeutics (TARA) Dips 2% as Stock Hovers Near SupportCharm Flow - The Legal Advocate
Protara Therapeuticsenters sales agreement with TD Cowen for common stock offering - marketscreener.com
Protara Therapeutics (NASDAQ: TARA) secures $100M ATM sales agreement with TD Cowen - Stock Titan
Protara Therapeutics (TARA) Q1 2026 Earnings: Narrower Loss Beats Street Estimates on Cost Management - The Legal Advocate
TARA: TARA-002 shows strong efficacy and regulatory momentum in LM and NMIBC, with key H2 catalysts - TradingView
TARA: TARA-002 shows strong efficacy and regulatory momentum in LM and NMIBC, targeting broad markets - TradingView
Protara’s cell therapy shows treatment durability in mid-stage NMIBC study - MSN
[EFFECT] Protara Therapeutics, Inc. SEC Filing - Stock Titan
Protara Therapeutics Q1 2026 Earnings: EPS Beats Estimates Amid Continued Pipeline ProgressEstimate Accuracy - newsline.com
Piper Sandler initiates coverage of Protara Therapeutics (TARA) with overweight recommendation - MSN
Protara Therapeutics Inc stock (US87612E1064): analyst optimism contrasts with volatile share price - AD HOC NEWS
A Quick Look at Today's Ratings for Protara Therapeutics(TARA.US), With a Forecast Between $24 to $28 - Moomoo
Protara Therapeutics (TARA) Receives a Buy from Oppenheimer - The Globe and Mail
Analysts’ Top Healthcare Picks: Protara Therapeutics (TARA), Elevance Health (ELV) - The Globe and Mail
Piper Sandler Maintains Protara Therapeutics(TARA.US) With Buy Rating, Announces Target Price $24 - Moomoo
Protara Therapeutics, Inc. (TARA) Discusses Interim Safety and Durability Data From STARBORN-1 Trial of TARA-002 in Lymphatic MalformationsSlideshow (NASDAQ:TARA) 2026-05-20 - Seeking Alpha
A Quick Look at Today's Ratings for Protara Therapeutics(TARA.US), With a Forecast Between $25 to $27 - Moomoo
TARA Maintained by Oppenheimer -- Price Target Raised to $28.00 - GuruFocus
Oppenheimer Adjusts Protara Therapeutics PT to $28 From $25, Maintains Outperform Rating - Moomoo
Protara Therapeutics Inc Lymphatic Malformations KOL Webinar Transcript - GuruFocus
Cantor Fitzgerald reiterates Protara Therapeutics stock rating By Investing.com - Investing.com Canada
Cantor Fitzgerald reiterates Protara Therapeutics stock rating - Investing.com
Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - The Manila Times
Protara Therapeutics Inc (TARA) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):